Cargando…

A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer

BACKGROUND: The aim of this study is to outline a general process for assessing the feasibility of performing a valid network meta-analysis (NMA) of randomized controlled trials (RCTs) to synthesize direct and indirect evidence for alternative treatments for a specific disease population. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cope, Shannon, Zhang, Jie, Saletan, Stephen, Smiechowski, Brielan, Jansen, Jeroen P, Schmid, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077675/ https://www.ncbi.nlm.nih.gov/pubmed/24898705 http://dx.doi.org/10.1186/1741-7015-12-93

Ejemplares similares

The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes
por: Smiechowski, Brielan B., et al.
Publicado: (2013)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
por: Jansen, Jeroen P, et al.
Publicado: (2012)

Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making
por: Cope, Shannon, et al.
Publicado: (2013)

Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non‐Hodgkin lymphoma
por: Wu, Ke, et al.
Publicado: (2019)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

A phase Ib study of everolimus combined with metformin for patients with advanced cancer
por: Molenaar, Remco J., et al.
Publicado: (2017)

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
por: Kordes, Sil, et al.
Publicado: (2012)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Everolimus treatment in advanced solid tumors: a personal view
por: Pusceddu, Sara, et al.
Publicado: (2015)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
por: Schmid, Peter, et al.
Publicado: (2021)

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
por: Bachelot, Thomas, et al.
Publicado: (2013)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe
por: Jerusalem, Guy, et al.
Publicado: (2015)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
por: Takatori, Eriko, et al.
Publicado: (2014)

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012)

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
por: Cascone, T., et al.
Publicado: (2021)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
por: Starks, David, et al.
Publicado: (2023)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia
por: Cope, Shannon, et al.
Publicado: (2019)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
por: Abida, Wassim, et al.
Publicado: (2016)

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
por: Weinberg, Benjamin A., et al.
Publicado: (2020)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
por: Vitali, Eleonora, et al.
Publicado: (2020)

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial
por: Lombard-Bohas, Catherine, et al.
Publicado: (2015)

Classical dynamics: a contemporary approach
por: Jose, Jorge V, et al.
Publicado: (1998)

Everolimus‐induced gastric antral vascular ectasia in advanced renal cancer
por: Hata, Kenichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_669pip13dnbvo2md9bvf1ovsm9